Rationale and design of a multi-center, prospective randomized controlled trial on the effects of sacubitril-valsartan versus enalapril on left ventricular remodeling in ST-elevation myocardial infarction: The PERI-STEMI study.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical cardiology"
DOI: 10.1002/clc.23744
Abstract: BACKGROUND Angiotensin receptor neprilysin inhibitor (ARNI) sacubitril-valsartan has been recommended as one of the first-line therapies in heart failure with reduced ejection fraction. However, whether ARNI could benefit patients with ST-segment elevation myocardial infarction (STEMI)… read more here.
Keywords: trial; sacubitril valsartan; enalapril; elevation myocardial ... See more keywords
A per‐protocol initiation of sacubitril/valsartan in an advanced heart failure disease management programme in the Middle East Gulf Region
Sign Up to like & getrecommendations! Published in 2019 at "ESC Heart Failure"
DOI: 10.1002/ehf2.12452
Abstract: The aim of this study is to evaluate the utilization and success in therapy intensification after initiation of sacubitril/valsartan using a specified protocol within an advanced heart failure and transplant programme in the Middle East… read more here.
Keywords: advanced heart; heart; sacubitril valsartan; heart failure ... See more keywords
Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort
Sign Up to like & getrecommendations! Published in 2019 at "ESC Heart Failure"
DOI: 10.1002/ehf2.12527
Abstract: Sacubitril/valsartan is safe when initiated during hospitalization in a clinical trial setting. Its safety in real‐life population is not stablished. We compared the initiation of sacubitril/valsartan during hospitalization in a non‐selected population, in the PIONEER‐HF… read more here.
Keywords: initiated hospitalization; sacubitril valsartan; non selected;
Sacubitril/valsartan in heart failure and end‐stage renal insufficiency
Sign Up to like & getrecommendations! Published in 2019 at "ESC Heart Failure"
DOI: 10.1002/ehf2.12544
Abstract: The aim of this report is to describe the feasibility and tolerability of medical treatment with sacubitril/valsartan in a patient treated with hemodialysis. We describe the case of a 67‐year‐old man with heart failure with… read more here.
Keywords: renal insufficiency; heart; sacubitril valsartan; heart failure ... See more keywords
Sacubitril‐Valsartan in a routine community population: attention to volume status critical to achieving target dose
Sign Up to like & getrecommendations! Published in 2020 at "ESC Heart Failure"
DOI: 10.1002/ehf2.12547
Abstract: In the PARADIGM‐heart failure trial, sacubitril‐valsartan demonstrated a reduction in heart failure admissions and reduced all‐cause mortality in patients with heart failure with reduced ejection fraction. Although real world data have shown similar benefits regarding… read more here.
Keywords: achieving target; target dose; sacubitril valsartan; heart failure ... See more keywords
Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
Sign Up to like & getrecommendations! Published in 2020 at "ESC Heart Failure"
DOI: 10.1002/ehf2.12713
Abstract: The use of sacubitril/valsartan significantly reduces death or hospitalization in patients with ejection fraction < 40%. There is no study evaluating this drug effects in non‐compaction cardiomyopathy (NCCM) individuals. read more here.
Keywords: compaction cardiomyopathy; non compaction; use sacubitril; sacubitril valsartan ... See more keywords
Reverse electromechanical modelling of diastolic dysfunction in spontaneous hypertensive rat after sacubitril/valsartan therapy
Sign Up to like & getrecommendations! Published in 2020 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13013
Abstract: Hypertension is a significant risk for the development of left ventricular hypertrophy, diastolic dysfunction, followed by heart failure and sudden cardiac death. While therapy with sacubitril/valsartan (SV) reduces the risk of sudden cardiac death in… read more here.
Keywords: heart; sacubitril valsartan; dysfunction; therapy ... See more keywords
Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
Sign Up to like & getrecommendations! Published in 2021 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13285
Abstract: Despite well‐established benefits of sacubitril/valsartan for cardiac reverse remodelling and the prognosis of patients with heart failure with reduced ejection fraction (HFrEF), there are some patients with limited therapeutic response, even with optimal therapy. We… read more here.
Keywords: reverse remodelling; sacubitril valsartan; heart failure;
The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "ESC heart failure"
DOI: 10.1002/ehf2.13677
Abstract: AIMS We aimed to investigate whether sacubitril-valsartan could further improve the prognosis, cardiac function, and left ventricular (LV) remodelling in patients following acute myocardial infarction (AMI). METHODS AND RESULTS We searched the PubMed, Embase, Cochrane… read more here.
Keywords: acute myocardial; myocardial infarction; sacubitril valsartan; meta analysis ... See more keywords
Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index.
Sign Up to like & getrecommendations! Published in 2022 at "ESC heart failure"
DOI: 10.1002/ehf2.13891
Abstract: AIMS This study aims to investigate the role of echocardiographically determined left ventricular output indices on sacubitril/valsartan titration in a cohort of outpatients with heart failure and reduced ejection fraction (HFrEF). METHODS AND RESULTS We… read more here.
Keywords: volume index; sacubitril valsartan; titration; stroke volume ... See more keywords
Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients
Sign Up to like & getrecommendations! Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13937
Abstract: Radiofrequency catheter ablation (RFCA) is now an established therapeutic option for patients with atrial fibrillation (AF), but the long‐term recurrence rate of AF is still high. Sacubitril/valsartan (Sac/Val) is superior to valsartan in attenuating ventricular… read more here.
Keywords: sacubitril valsartan; valsartan attenuates; attenuates atrial; atrial structural ... See more keywords